For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Cartesian Therapeutics Inc (NASDAQ: RNAC) closed at $6.76 up 5.13% from its previous closing price of $6.43. In other words, the price has increased by $5.13 from its previous closing price. On the day, 0.11 million shares were traded. RNAC stock price reached its highest trading level at $6.82 during the session, while it also had its lowest trading level at $6.41.
Ratios:
For a deeper understanding of Cartesian Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.33 and its Current Ratio is at 10.67.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on July 09, 2025, initiated with a Outperform rating and assigned the stock a target price of $38.
On December 19, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 04 ’25 when BARABE TIMOTHY C bought 30,000 shares for $6.86 per share. The transaction valued at 205,797 led to the insider holds 54,366 shares of the business.
CHRISTOPHER M JEWELL bought 26,935 shares of RNAC for $192,585 on Nov 19 ’25. On Apr 10 ’25, another insider, SPRINGER TIMOTHY A, who serves as the Director of the company, bought 48,595 shares for $10.47 each. As a result, the insider paid 508,751 and bolstered with 620,175 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNAC now has a Market Capitalization of 175784384 and an Enterprise Value of 45003376. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.67. Its current Enterprise Value per Revenue stands at 41.25 whereas that against EBITDA is -0.555.
Stock Price History:
The Beta on a monthly basis for RNAC is 0.38, which has changed by -0.6765593 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, RNAC has reached a high of $20.30, while it has fallen to a 52-week low of $5.98. The 50-Day Moving Average of the stock is -13.57%, while the 200-Day Moving Average is calculated to be -35.15%.
Shares Statistics:
For the past three months, RNAC has traded an average of 156.21K shares per day and 212210 over the past ten days. A total of 26.00M shares are outstanding, with a floating share count of 9.42M. Insiders hold about 63.78% of the company’s shares, while institutions hold 19.49% stake in the company. Shares short for RNAC as of 1764288000 were 2080754 with a Short Ratio of 15.00, compared to 1761868800 on 2128562. Therefore, it implies a Short% of Shares Outstanding of 2080754 and a Short% of Float of 20.1.
Earnings Estimates
A comprehensive evaluation of Cartesian Therapeutics Inc (RNAC) is underway, with the input of 1 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.81 and low estimates of -$0.93.
Analysts are recommending an EPS of between -$1.93 and -$1.93 for the fiscal current year, implying an average EPS of -$1.93. EPS for the following year is -$2.58, with 1.0 analysts recommending between -$2.58 and -$2.58.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for RNAC’s current fiscal year. The highest revenue estimate was $2.3M, while the lowest revenue estimate was $1.85M, resulting in an average revenue estimate of $1.97M. In the same quarter a year ago, actual revenue was $38.91M
